This drug is metabolized to its inactive metabolite, 2',2'-difluorodeoxyuridine following intravenous injection, and is metabolized by the liver in linear kinetic rates and finally excreted in the urine. It has a half-life of about 12 hours in vitro.
This drug has shown efficacy either alone or in combination with carboplatin against canine transitional cell carcinoma, nasal carcinoma, osteosarcoma, hepatic carcinoma and mammary tumors.
- ↑ Med Help
- ↑ Freise KJ et al (2006) Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. J Vet Pharmacol Ther 29(2):147-152
- ↑ de Brito Galvao JF et al (2012) Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines. Am J Vet Res 73(8):1262-1272
- ↑ LeBlanc AK et al (2004) Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 45(5):466-470
- ↑ McMahon M et al (2011) Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. J Vet Intern Med 25(3):511-517
- ↑ Elpiner AK et al (2011) Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas. Vet Comp Oncol 9(4):260-268
- ↑ Marconato L et al (2008) Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 6(2):90-101
- ↑ Turner AI et al (2006) Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med 20(6):1384-1388
- ↑ Cozzi PJ et al (1999) Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5(9):2629-2637
- ↑ Kosarek CE et al (2005) Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 19(1):81-86
- ↑ Dominguez PA et al (2008) Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern Med 23(1):130-137